Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura

Historical review - the birth of the haemolytic uraemic syndrome, commentary on the relationships between HUS and TTP, with musings on the problems concerning the definition of a syndrome; epidemiology of HUS - the haemolytic uraemic syndromes in the United Kingdom, childhood haemolytic uraemic syndrome in Canada - a multicentre study, haemolytic uraemic syndrome in Asia, HUS in Johannesburg, South Africa - epidemiology and long-term-follow-up, the haemolytic uraemic syndrome in Argentina; clinical manifestations of HUS - gastrointestinal features of the haemolytic uraemic syndrome, central nervous system involvement in the haemolytic uraemic syndrome, pancreatic involvement in the haemolytic uraemic syndrome, cardiovascular involvement in the haemolytic syndrome; atypical haemolytic uraemic syndrome, haemolytic uraemic syndrome and transplantation, bone marrow transplantation-associated thrombotic microangiopathy; causes of HUS - the association of verocytotoxins and the classical haemolytic uraemic syndrome, haemolytic uraemic syndrome in families, an analysis of the association of the haemolytic uraemic syndrome and the birth control pill, haemolytic uraemic syndrome in association with pregnancy, inborn errors of cobalamin metabolism and the haemolytic uraemic syndrome, cancer and chemotherapy-associated thrombotic microangiopathy, haemolytic uraemic syndrome/thrombotic thrombocytopenic purpura associated with human immunodeficiency virus and acquired immunodeficiency syndrome; pathology - pathology of the haemolytic uraemic syndrome; pathogenesis - oxygen-derived free radicals in the pathogenesis of the haemolytic uraemic syndrome, haemolytic uraemic syndrome, thrombotic thrombocytopenic purpura, the generalized Shwartzman reaction, coagulation, and fibrinolysis, the pivotal role of the endothelial cell in the pathogenesis of HUS, pathogenesis of Shiga toxin (verotoxin)-induced endothelial cell injury; treatment - treatment of haemolytic uraemic syndrome with antithrombotic agents, treatment of haemolytic uraemic syndrome with fresh-frozen plasma or with plasmapheresis, long-term outcome of haemolytic uraemic syndrome in children, follow-up of haemolytic uraemic syndrome in Argentina; thrombotic thrombocytopenic purpura - von Willebrand factor abnormalities in thrombotic thrombocytopenic purpura and the haemolytic uraemic syndrome, platelet-agglutinating/aggregating proteins from the plasma of patients with thrombotic thrombocytopenic purpura, role of prostacyclin in the pathogenesis and therapy of thrombotic thrombocytopenic purpura, pathological features of thrombotic thrombocytopenic purpura, an animal model of thrombotic thrombocytopenia with von Willebrand factor deficiency - the role of botrocetin in studies of human TTP, treatment of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome - the role of Vincristine, antiplatelet agents on thrombotic thrombocytopenic purpura. (Part contents)